What RapidAI and Neurophet Announced About Alzheimer's and MS Treatment Monitoring

In an announcement dated 2 November 2026 and carried on the RapidAI site, Neurophet and RapidAI said they had partnered to widen access to brain scan measurement for Alzheimer's disease and multiple sclerosis treatment monitoring. The announcement names the Neurophet products involved as AQUA AD Plus, SCALE PET, AQUA MS, AQUA and a research tool it calls tES/TMS LAB, and says they are designed to support treatment monitoring. It says the work reaches clinicians through the Rapid Enterprise Platform, Rapid Navigator Pro and the Rapid Mobile App, and it names the two Alzheimer's treatments Leqembi and Kisunla as the context for the monitoring. Neurophet co-chief executives Jake Junkil Been and Donghyeon Kim are quoted, as is RapidAI founder Dr. Greg Albers. The announcement makes no claim of FDA clearance, states no K number and names no CE marking, and it reports no patient numbers and no accuracy figures.

Why the RapidAI and Neurophet Partnership Matters to Neurology and Imaging Leaders

This one matters because of what the new Alzheimer's drugs created, which is a monitoring workload rather than a reading backlog. A patient on one of these treatments needs brain scans compared over time and specific changes watched for, and that is measurement work rather than spotting a finding. Hospitals that take on these drugs have to find that capacity somewhere. Putting the measurement on a platform the hospital already runs is the cheap way in, and that is the real content of the announcement. Be careful with two things. The announcement claims no regulatory status for any of the named products, and this site's own FDA directory holds no record under the Neurophet name, so treat these as tools described by their makers until you check the federal record yourself. And designed to support treatment monitoring is a sentence about intent, not evidence. Nothing here reports how the measurements compare with a specialist reading the same scans.

Where the RapidAI Update Comes From

RapidAI is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

RapidAI original source.

How We Would Research the RapidAI and Neurophet Partnership

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would search the federal device database for each named Neurophet product, because the announcement claims no clearance and this site's own FDA directory holds no Neurophet record.
  2. Then we would ask what a hospital has to do to turn the Neurophet tools on inside a platform it already licenses, since the whole value of this is that it should be a small step.
  3. We would ask a neurology team using it how the measurement compares with their own radiologist reading the same scans over time, because treatment monitoring lives or dies on consistency between reads.